Font Size:
Mylan to Acquire King for US$4 B
Business Review Editor
Abstract
Mylan Laboratories entered into an agreement to acquire King Pharmaceuticals thus substantially expanding its pharmaceutical product portfolio. The deal could be worth up to US$4 B to King Pharmaceuticals.
Add comment
This work is licensed under a Creative Commons Attribution 3.0 License.